NASDAQ:DRTX - Durata Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Receive DRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Has Durata Therapeutics been receiving favorable news coverage?

Media coverage about DRTX stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Durata Therapeutics earned a news impact score of 0.01 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Durata Therapeutics?

Shares of DRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Durata Therapeutics?

Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.

MarketBeat Community Rating for Durata Therapeutics (DRTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe DRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Durata Therapeutics (NASDAQ:DRTX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/20/2016 forward)


Durata Therapeutics (NASDAQ:DRTX) Earnings History and Estimates Chart

Earnings by Quarter for Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics (NASDAQ DRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details
5/8/2014Q114($0.61)($0.65)ViewN/AView Earnings Details
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.60)($0.45)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details
9/4/2012Q2 2012($1.08)($256.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Durata Therapeutics (NASDAQ:DRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Durata Therapeutics (NASDAQ DRTX) Insider Trading and Institutional Ownership History

Insider Trading History for Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics (NASDAQ DRTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.0015,000View SEC Filing  
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.001,000View SEC Filing  
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Durata Therapeutics (NASDAQ DRTX) News Headlines

Paratek: A Review Of Progress And Preview Of 2018Paratek: A Review Of Progress And Preview Of 2018 - March 21 at 4:12 PM
Critical Survey: Arena Pharmaceuticals (ARNA) and Durata Therapeutics (DRTX)Critical Survey: Arena Pharmaceuticals (ARNA) and Durata Therapeutics (DRTX) - March 3 at 4:04 PM
Head-To-Head Contrast: Durata Therapeutics (DRTX) vs. Blueprint Medicines (BPMC)Head-To-Head Contrast: Durata Therapeutics (DRTX) vs. Blueprint Medicines (BPMC) - February 26 at 10:48 AM

SEC Filings

Durata Therapeutics (NASDAQ:DRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Durata Therapeutics (NASDAQ:DRTX) Income Statement, Balance Sheet and Cash Flow Statement


Durata Therapeutics (NASDAQ DRTX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.